Advertisement

Prognostic implication of adjuvant/neoadjuvant chemotherapy consisting of doxorubicin and ifosfamide in patients with extraskeletal osteosarcoma

  • Toru Wakamatsu
  • Shigeki Kakunaga
  • Satoshi Takenaka
  • Hidetatsu Outani
  • Kenichiro Hamada
  • Yoshinori Imura
  • Yumiko Hori
  • Norifumi Naka
  • Ikuo Kudawara
  • Hideki Yoshikawa
  • Takafumi UedaEmail author
Original Article
  • 35 Downloads

Abstract

Background

Extraskeletal osteosarcoma (ESOS) is an extremely rare soft tissue sarcoma. Their prognosis remains poor. Our purposes were to identify the effective chemotherapeutic regimen for ESOS.

Methods

We retrospectively reviewed 16 patients with ESOS treated at the Osaka University Orthopaedic Oncology Group between 1992 and 2012. We extracted the clinical data on patients. Kaplan–Meier method and the log-rank test were used for survival analyses.

Results

Median age of the patients was 61.5 years (range 25–79 years). Wide local excision was performed for 11 patients and 9 patients were treated combined with chemotherapy. The 5-year disease-specific survival (DSS) rate was 53.9%. The 5-year DSS rates for patients treated with adjuvant/neoadjuvant chemotherapy or not were 66.7% or 25%, respectively (p = 0.0215). Furthermore, the 5-year DSS rates for patients treated with adjuvant/neoadjuvant chemotherapy consisting of doxorubicin and ifosfamide and those treated with other regimens were 100% or 40%, respectively (p = 0.0327).

Conclusion

The present study demonstrated that adjuvant/neoadjuvant chemotherapy, especially consisting of doxorubicin and ifosfamide, was potentially efficacious for ESOS. Further prospective study using this multimodality treatment approach to patients with ESOS should be strongly warranted.

Keywords

Extraskeletal osteosarcoma Chemotherapy Doxorubicin Ifosfamide 

Notes

Acknowledgements

We thank all the participants who treated ESOS patients of current study in Osaka University Orthopaedic Oncology Group.

Funding

We have no funding.

Compliance with ethical standards

Conflict of interest

All authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

 Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Allan CJ, Soule EH (1971) Osteogenic sarcoma of the somatic soft tissues: clinicopathologic study of 26 cases and review of literature. Cancer 27:1121–1133CrossRefGoogle Scholar
  2. 2.
    Chung EB, Enzinger FM (1978) Extraskeletal osteosarcoma. Cancer 1987(60):1132–1142Google Scholar
  3. 3.
    Rao U, Cheng A, Didolkar MS (1978) Extraosseous osteogenic sarcoma: clinicopathological study of eight cases and review of literature. Cancer 41:1488–1496CrossRefGoogle Scholar
  4. 4.
    Sordillo PP, Hajdu SI, Magill GB et al (1983) Extraosseous osteogenic sarcoma: a review of 48 patients. Cancer 51:727–734CrossRefGoogle Scholar
  5. 5.
    Bane BL, Evans HL, Ro JY et al (1990) Extraskeletal osteosarcoma: a clinicopathologic review of 26 cases. Cancer 65:2762–2770CrossRefGoogle Scholar
  6. 6.
    Ahmad SA, Patel SR, Ballo MT et al (2002) Extraosseous osteosarcoma: response to treatment and long-term outcome. J Clin Oncol 20:521–527CrossRefGoogle Scholar
  7. 7.
    Goldstein-Jackson SY, Gosheger G, Delling G et al (2005) Cooperative Osteosarcoma Study Group COSS. Extraskeletal osteosarcoma has a favourable prognosis when treated like conventional osteosarcoma. J Cancer Res Clin Oncol 131:520–526CrossRefGoogle Scholar
  8. 8.
    Lee JS, Fetsch JF, Wasdhal DA et al (1995) A review of 40 patients with extraskeletal osteosarcoma. Cancer 76:2253–2259CrossRefGoogle Scholar
  9. 9.
    Lee S, Lee MR, Lee SJ et al (2010) Extraosseous osteosarcoma: single institutional experience in Korea. Asia Pac J Clin Oncol 6:126–129CrossRefGoogle Scholar
  10. 10.
    Patel SR, Benjamin RS (1995) Primary extraskeletal osteosarcoma: experience with chemotherapy. J Natl Cancer Inst 87:1331–1333CrossRefGoogle Scholar
  11. 11.
    Choi LE, Healey JH, Kuk D et al (2014) Analysis of outcomes in extraskeletal osteosarcoma: a review of fifty-three cases. J Bone Jt Surg Am 96(1):e2(1−8)CrossRefGoogle Scholar
  12. 12.
    Sio TT, Vu CC, Sohawon S et al (2016) Extraskeletal osteosarcoma: an international rare cancer network study. Am J Clin Oncol 39:32–36CrossRefGoogle Scholar
  13. 13.
    Torigoe T, Yazawa Y, Takagi T et al (2007) Extraskeletal osteosarcoma in Japan: multiinstitutional study of 20 patients from the Japanese Musculoskeletal Oncology Group. J Orthop Sci 12:424–429CrossRefGoogle Scholar
  14. 14.
    Fan Z, Patel S, Lewis VO et al (2015) Should high-grade extraosseous osteosarcoma be treated with multimodality therapy like other soft tissue sarcomas? Clin Orthop Relat Res 473:3604–3611CrossRefGoogle Scholar
  15. 15.
    Longhi A, Bielack SS, Grimer R et al (2017) Extraskeletal osteosarcoma: a European Musculoskeletal Oncology Society study on 266 patients. Eur J Cancer 74:9–16CrossRefGoogle Scholar
  16. 16.
    Nystrom LM, Reimer NB, Reith JD et al (2016) The treatment and outcomes of extraskeletal osteosarcoma: institutional experience and review of the literature. Iowa Orthop J 36:98–103Google Scholar
  17. 17.
    Paludo J, Fritchie K, Haddox CL et al (2018) Extraskeletal osteosarcoma: outcomes and the role of chemotherapy. Am J Clin Oncol 41(9):832–837CrossRefGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2019

Authors and Affiliations

  • Toru Wakamatsu
    • 1
    • 3
  • Shigeki Kakunaga
    • 2
  • Satoshi Takenaka
    • 1
  • Hidetatsu Outani
    • 1
  • Kenichiro Hamada
    • 1
  • Yoshinori Imura
    • 1
    • 3
  • Yumiko Hori
    • 4
  • Norifumi Naka
    • 1
    • 3
  • Ikuo Kudawara
    • 2
  • Hideki Yoshikawa
    • 1
  • Takafumi Ueda
    • 2
    Email author
  1. 1.Department of Orthopaedic SurgeryOsaka University Graduate School of MedicineSuitaJapan
  2. 2.Department of Orthopaedic SurgeryNational Hospital Organization Osaka National HospitalOsakaJapan
  3. 3.Department of Musculoskeletal Oncology ServiceOsaka International Cancer InstituteOsakaJapan
  4. 4.Department of PathologyOsaka University Graduate School of MedicineSuitaJapan

Personalised recommendations